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CNS and elsewhere and by tissue-specific progenitor cells of a variety of non-neural lineages.
The onset of NG2 expression in the oligodendrocyte lineage occurs immediately after induction of the SoxE family of high-mobility-group transcription factors Sox9 and Sox10, which are induced by the basic helix-loop-helix transcription factor Olig2 (Weider & Wegner, 2017) . This coincides with oligodendrocyte lineage specification. NG2 is highly expressed on migrating, proliferating progenitor cells and is downregulated upon terminal oligodendrocyte differentiation. NG2 expression is upregulated in a variety of pathological states, such as demyelination (Reynolds, Cenci di Bello, Dawson, & Levine, 2001) , spinal cord injury (Jones, Yamaguchi, Stallcup, & Tuszynski, 2002) , and neoplasia (Shoshan et al., 1999 , Stallcup & Huang, 2008 .
Despite the well-known changes in NG2 expression under various physiological and pathological conditions and the widespread use of NG2 as a marker for NG2 glia, little is known about the transcriptional regulation of the Cspg4 gene. In transgenic mouse lines in which expression cassettes are inserted into the first exon of the mouse Cspg4 gene placed in the center of a 200 kb bacterial artificial chromosome (BAC), faithful expression of DsRed (Zhu, Bergles, & Nishiyama, 2008) , EGFP (Hughes, Kang, Fukaya, & Bergles, 2013) , and Cre/CreER™ (Zhu et al., 2008 (Zhu et al., , 2011 
| MATERIALS AND METHODS

| Analysis of conserved regions within the Cspg4 gene
To identify the regions of the mouse Cspg4 gene that were conserved among species, we analyzed the Cspg4 gene using VISTA browser in the Vista program (Genomics Division, Lawrence Berkeley National Laboratory and US Department of Energy Joint Genome Institute, http://genome.lbl.gov/vista/index.shtml; Visel, Minovitsky, Dubchak, & Pennacchio, 2007) and the University of California Santa Cruz (UCSC) Genome Browser. Nucleotide positions are based on the December 2011 Mus musculus assembly (Genome Reference Consortium Mouse Build 38 (GRCm38; GCA_000001635.2). We identified the following noncoding regions that were conserved among mammals: 3.0 kb promoter and 1.5 kb promoter in the promoter region; intron 1-1 (int1-1), intron 1-2 (int1-2), intron1-3 (int1-3), intron 8 (int8) in intronic sequences; and two regions in the 3 0 untranslated region (3 0 -UTR1 and 3 0 -UTR2) ( Figure 1a ). The int1-3 region was further subdivided into int1-3a, b, and c subregions, and int1-3b was further subdivided into int1-3bi, 1-3bii, and 1-3biii. The nucleotide positions of these regions are listed in Supporting Information, Table 1 . Transcription factor binding sites in int1-3 were searched in the UCSC Genome Browser.
| Plasmids
For electroporation into chick embryos and transfecting mixed glial cultures, we used the transposon vector pT2AL200R175-CAGGS-EGFP (kindly provided by Dr. Koichi Kawakami) (Kawakami & Noda, 2004; Urasaki, Morvan, & Kawakami, 2006) and replaced the chicken beta-actin (CAG) promoter with PCR-amplified promoter/ enhancer regions of the mouse Cspg4 gene, and inserted it upstream of the SV40 minimal promoter. The SV40 minimal promoter showed little basal activity in chick, but we saw significant background activity in astrocytes when used in mixed glial cultures. Therefore, in subsequent experiments, we switched to using the β-globin minimal promoter (Yee & Rigby, 1993) . For electroporation into mouse brain, the Cspg int1-3b enhancer and β-globin minimal promoter were inserted into the transposon vector upstream of EGFP. For luciferase assays, int1-3bi, int1-3bii, or int1-3biii was PCR-amplified together with the β-globin minimal promoter and inserted into pGL3-Basic vector (Promega) expressing Firefly luciferase. Scrambled mutations were introduced into Sox BE1, Sox BE2, Sox BE3, bHLH BE1, BE3, and bHLH BE4 sequences. For generating transgenic mice, int1-3b enhancer was inserted upstream of heat-shock protein 68 (hsp68) minimal promoter to drive EGFP transcription. For these experiments, we switched to using the hsp68 minimal promoter because it had been shown that the hsp68 minimal promoter gives a low background activity on its own but strong activity when combined with active promoter/enhancer elements in transgenic mice (Kothary et al., 1989) . All the primer sequences used for the construction of the plasmids are listed in Supporting Information, Table 2 .
| Cell culture and transfection
For mixed glial cultures, postnatal day 0-3 (P0-3) mouse forebrains were dissociated into single cells with trypsin and plated onto poly-Llysine-coated glass coverslips. The cells were then directly transfected or passaged once and transfected. Oli-neu mouse oligodendrocyte precursor cell line (Jung et al., 1995, a 
| Animals
ICR mice were obtained from SLC (Shizuoka, Japan), FVB mice from Jackson Laboratory (Bar Harbor, Maine), and CD1 mice were from Charles River Laboratories (Wilmington, MA) and were bred in our animal facilities. For perinatal electroporation, mice were anesthetized by hypothermia,~1 μg of the plasmids were injected into the lateral ventricle, and 4 square pulses of 100 V and 50 ms each were applied using a NEPA21 electroporator (Nepa Gene, Japan; Bulldog Bio).
Transgenic mice were generated in the Gene Transfer and Transgenic
Mouse Facility of the University of Connecticut Health Center by injecting linearized plasmids into fertilized CD1 oocytes and transferring them into pseudopregnant mice. Fertilized chick eggs were obtained from a local breeder (Yamagishi, Japan) and were incubated at 37 C. The embryonic stage was determined according to Hamburger and Hamilton (1951) . For electroporation, plasmid vectors were injected into the neural tube, and three electric pulses of 30 V and 50 ms each were applied. All animal procedures were approved by the animal care committee of University of Connecticut or Kyoto Prefectural University of Medicine.
| Immunohistochemistry
Brain, cerebellum, and spinal cords were fixed in 4% paraformaldehyde in phosphate-buffered saline by intracardiac perfusion. Sections were cut using a cryostat or vibratome (Leica, Germany) and subjected to immunohistochemical staining as previously described (Zhu et al., 2011) . Primary antibodies used for immunohistochemistry were rabbit anti-GFP (1:200, Invitrogen), chick anti-GFP (1:1000, Abcam and Aves); rabbit anti-NeuN (1:1000, Cell Signaling Technology), rabbit anti-NG2 (1:500, Millipore), rabbit anti-Olig2 (1:500, Millipore); mouse anti-Olig2 (1:1000, Novus Biologicals); mouse anti-GFAP (1:1000, Sigma-Aldrich); and rat anti-CD11 (1:100, Serotec, UK). Stained sections were observed under Zeiss Axiovert M200 fluorescent microscope or confocal microscope (Olympus FV1000; Leica TCS SP2 and SP8).
| Chromatin immunoprecipitation (ChIP) analysis
ChIP analysis was performed as described by Carey et al. (2009) and in the manual for SimpleChIP Plus Sonication Kit (Cell Signaling).
Approximately 2 × 10 7 Oli-neu cells grown in 10 ml of medium in a 10 cm dish were cross-linked with 1% methanol-free formaldehyde (Cell Signaling) for 20 min followed by quenching with 0.137 M glycine. Cross-linked cells were harvested and washed in cold PBS and stored frozen at −80 C. To prepare nuclear lysate, cells were first at 65 C for 2 hr, and DNA was purified using NucleoSpin Gel and PCR Clean-up columns (Macherey-Nagel). The purified DNA was subjected to PCR using int1-3b and intron 2 primers from the mouse Cspg4 gene (Supporting Information, Table 2 ) and the products were separated on 1.8% agarose gels.
| ChIP sequencing datasets and analysis
ChIP-seq datasets from epiblast stem cell-derived OPCs were retrieved from GEO (accession # not yet obtained). Adapter and quality trimming was performed using the FASTX-Toolkit (http:// hannonlab.cshl.edu/fastx_toolkit/). Data were aligned to the mm9 genome using Bowtie v0.12.9 (Langmead, Trapnell, Pop, & Salzberg, 2009 ). Multi-aligned reads and PCR duplicates were discarded. WIG tracks were generated using MACS v1.4 (Zhang et al., 2008) , then normalized by the median signal and converted to bigwig format using wigToBigWig (http://hgdownload.cse.ucsc.edu/admin/exe/).
Tracks were visualized using IGV (Thorvaldsdottir, Robinson, & Mesirov, 2013) . 
| Luciferase assays
| Electrophoretic mobility shift assays
The DNA binding regions of mouse Sox10 (amino acid 1-235), fulllength Olig2, and Ascl1 were cloned into pT7CFE1-cMyc vector (ThermoFisher). in vitro translation was performed using the TNT Quick Coupled transcription/translation system (Promega 
.1 | Chick in ovo electroporation
We searched the mouse Cspg4 gene for regions that were highly conserved among mammals, which could represent potential enhancer regions. The most highly conserved non-coding regions were found in Neither did the 3.0 kb promoter yield Olig2+ EGFP+ cells (not shown).
To identify an enhancer region that could direct NG2 expression in NG2 glial cells, we generated additional Tol2 donor vectors containing other conserved regions of the Cspg4 genes upstream of EGFP cDNA
( Figure 1a ) and tested them by in ovo electroporation. EGFP+ cells were detected with intron 1-3 (int1-3, Figure 1c ,d) and to a lesser degree with intron 8 (int8) constructs but not with constructs from intron 1-1 (int1-1), intron 1-2 (int1-2), or 3 0 -untranslated regions 1 or 2 (UTR-1 or UTR-2). The large majority of the EGFP+ cells (96.1%) in embryos electroporated with the int1-3 construct expressed Olig2, whereas only 12.2% of the EGFP+ cells in embryos electroporated with the int8 construct were Olig2+ (Figure 1d ). These results suggested that int1-3 corresponding to the 3 0 end of the first intron contained the regulatory elements of the mouse Cspg4 gene necessary for targeting Cspg4 expression to NG2 glial cells.
| Transfection into mixed glial cells from perinatal mouse brain
To further identify the region in the mouse Cspg4 gene required for To further map the cis-element required for the correct expression of Cspg4, we subdivided the 4.2-kb int1-3 region into three fragments (int1-3a, 1-3b, and 1-3c), each subregion representing a stretch of conserved sequences (Figure 1a ). When we transfected mixed glial cultures with EGFP reporter constructs driven by int1-3a or int1-3c, there was little or no EGFP expression in NG2 cells (Figure 2c, d, .
By contrast, the int1-3b-EGFP construct resulted in NG2 expression in 35.4 AE 7.1% of EGFP+ cells with polydendrocyte morphology, similar to that obtained with the entire int1-3-EGFP construct (Figure 2e , f,i) This suggests that the 1.45 kb int1-3b region contained a cis-acting element that was necessary for Cspg4 expression in NG2 cells. Interestingly, this region was the only region of the noncoding sequence of the Cspg4 gene that was also conserved in the chick.
| Cspg4 int1-3b targets EGFP expression to NG2 cells in transgenic mice
To analyze the specificity of the Cspg4 int1-3b enhancer, we generated transgenic mice by injecting fertilized oocytes with a transgene that contained int1-3b and hsp68 minimal promoter followed by the EGFP coding sequence (Figure 3a) . Two of the three founder lines In P14 Cspg4-EGFP1 mice, more than 80% of NG2+ glial cells in the neocortex, corpus callosum, and spinal cord white matter exhibited EGFP fluorescence, while the proportion of NG2 cells that showed EGFP fluorescence in the cerebellum and spinal cord gray matter was slightly lower, between 60% and 75% (Figure 3i ). At P60, more than 74% of NG2+ glial cells had EGFP fluorescence, while the proportion was lower in the gray matter ranging from 59% in the spinal cord to 72% in the neocortex (Figure 3j ). Overall, there was no statistically significant difference between the proportion of NG2+ cells that were EGFP+ at P14 and P60 in gray or white matter (p = .0540
and .9408, respectively, n = 3). The slight trend toward a decrease in P60 gray matter likely reflects the decline in NG2 mRNA expression with age (Nishiyama, Lin, Giese, Heldin, & Stallcup, 1996b) . EGFP fluorescence was sufficiently strong to visualize the cells without immunolabeling for EGFP, and EGFP+ NG2+ cells exhibited the typical polydendrocyte morphology.
We further evaluated the specificity and robustness of EGFP expression within the oligodendrocyte lineage in the neocortex and corpus callosum of Cspg4-EGFP1 mice at P14 and P60 (Figure 4) . At both ages, the proportion of EGFP+ cells that were NG2+ was greater in the superficial layers of the neocortex than in deeper cortical layers and corpus callosum. At P14, 87% of EGFP+ cells in cortical layers 2/3 were NG2+, whereas 70% and 63% of EGFP+ cells in layers 5/6 and corpus callosum were NG2+, respectively (Figure 4a, d, g, j, m, p) . This trend was more pronounced in P60 cerebrum, where 62%, 28%, and 16% of EGFP+ cells in layers 2/3, 5/6, and corpus callosum, respectively, were NG2+. As mature oligodendrocytes are more abundant in the older brain and exist in a gradient of increasing density from superficial cortical layers to the corpus callosum (Tomassy et al., 2014) , we quantified the proportion of EGFP+ cells that were CC1+
oligodendrocytes to determine whether the EGFP+ NG2− cells were oligodendrocytes. At P14, 3%, 24%, and 34% of EGFP+ cells in layers 2/3, 5/6, and corpus callosum, respectively, were labeled by the oligodendrocyte antibody CC1 (Figure 4b ,e,h,k,n,q). At P60, a greater proportion of EGFP+ cells were oligodendrocytes (38%, 71%, and 88% in layers 2/3, 5/6, and corpus callosum, respectively). NG2+ cells and 
| Binding of Sox10 and Olig2 to Cspg4 int1-3b enhancer
The nucleotide sequence of Cspg4 int1-3 enhancer revealed several potential binding sites for Sox and bHLH transcription factors.
To examine whether endogenous Sox and bHLH transcription factors were associated with the int1-3b enhancer of the endogenous Cspg4 gene, we performed chromatin immunoprecipitation (ChIP)-PCR on cross-linked extracts from Oli-neu cells, which are an oligodendrocyte precursor cell line that robustly expresses NG2 (Jung et al., 1995) . We immunoprecipitated Olig2 and Sox10 and analyzed the associated DNA by PCR using primers from int1-3b.
We used primers from intron 2 as negative control (Figure 5a ).
Int1-3b but not intron 2 sequences were detected in immunoprecipitates formed with antibodies to Olig2 and Sox10 but not with control rabbit IgG. Both int1-3b and intron 2 sequences were detected in total input chromatin and in immunoprecipitates formed with the positive control antibody to histone H3. This suggested that both Olig2 and Sox10 specifically bound to the Cspg4 int1-3b enhancer.
| Active histone posttranslational modifications at Cspg4 int1-3
We next examined whether the Cspg4 int1-3b region was enriched in histone posttranslational modifications that are known to be associ- Int1-3b and the surrounding regions were more enriched for both H3K4me1 and H3K27ac than intron 2 (Figure 5b) . Thus, the local chromatin state was consistent with enhancer activity at int1-3b but not intron 2 in NG2 cells.
| Cooperative activation of Cspg4 int1-3b enhancer by SoxE and bHLH proteins
The bHLH transcription factors Olig2 and Ascl1 are involved in oligodendrocyte specification, proliferation, and differentiation (Lu et al., (Finzsch, Stolt, Lommes, & Wegner, 2008; Stolt et al., 2002 Stolt et al., , 2003 Küspert & Wegner, 2016) . To examine whether SoxE and bHLH proteins modulate Cspg4 int1-3b enhancer activity, we performed luciferase assays in Neuro-2a mouse neuroblastoma cells (Schubert, Humphreys, Baroni, & Cohn, 1969) , which do not express NG2.
Neuro-2a cells were transfected with Cspg4-int1-3b-luciferase construct (int1-3b-luc) in combination with pCAG expression constructs containing SoxE and/or bHLH cDNAs, and luciferase activity was measured after 48 hr (Figure 6a ). Values were normalized to luciferase activity in cells cotransfected with int1-3b-luc and the pCAG control vector without any transcription factors.
When added alone, Ascl1 or the SoxE proteins Sox9 and Sox10
slightly increased Cspg4 int1-3b-luc activity. While Olig2 homodimer is known to function as a transcriptional repressor, Olig2 can activate transcription when it is heterodimerized with an E-box binding bHLH factor such as E47, (Küspert, Hammer, Bosl, & Wegner, 2011) .
Transfection of Olig2+E47 did not increase int1-3b-luciferase activity over control or Olig2 alone. However, expression of Sox9 in combination with Olig2+E47 resulted in a 3.6-fold increase in luciferase activity compared to Olig2+E47 and a 1.7-fold increase compared Sox9 alone. The combination of Sox10 and Olig2+E47 led to a 12.2-fold increase over Olig2+E47 and a 2.9-fold increase over Sox10 alone.
Similarly, combined expression of Sox10 and Ascl1 resulted in a 4.9-fold increase in luciferase activity compared with Ascl1 alone and a 2.8-fold increase over Sox10 alone. These observations suggest that int1-3b enhancer, and that SoxE and the bHLH proteins act synergistically to increase the enhancer activity.
| Identification of Sox10 binding sites
To identify Sox10 binding sites in the Cspg4 enhancer, we divided the 1.45 kb int1-3b segment into three smaller fragments of approximately 500 bp each (int1-3bi, 3bii, and 3biii) and tested them in luciferase assays in Neuro-2a neuroblastoma cells in the presence or absence of Sox10. When the full-length 1.45-kb int1-3b was used to drive luciferase, co-transfection of Sox10 significantly increased the luciferase activity ( Figure 6b , top 2 bars). We next performed luciferase assays with a series of deletion mutants that lacked progressively larger segments of int1-3bi, 3bii, and 3biii. We identified two 100 bp regions, one in int1-3bi and the other in int1-3biii that were responsive to activation by Sox10 (Figure 6b ), suggesting that there were at least two Sox10-binding regions within the int1-3b enhancer.
We searched int1-3bi and int1-3biii sequences for potential Soxbinding motifs that resembled the canonical Sox-binding motif (A/T) (A/T)CAA(A/T)G (Küspert & Wegner, 2016) and found two candidate sites, Sox-BE (binding element) 1 (CACAAAT) and Sox-BE2
(ACACAAAC), in int1-3bi and a third candidate site Sox-BE3 (TCAAAG) in int1-3biii (Supporting Information, Table 1 ). We generated int1-3bi luciferase constructs with scrambled mutations in Sox-BE1 and Sox-BE2 (Sox-BE1mut or Sox-BE2mut) and an int1-3biii luciferase construct with a scrambled mutation in Sox-BE3 (Sox-BE3mut) and measured luciferase activity after co-transfecting them into Neuro-2a cells with pCAG-Sox10 (Figure 6c ). Mutations in Sox-BE1 and Sox-BE2 sites reduced the Sox10-induced luciferase activity to 38.3% and 26.0% of that produced by wild type (wt) int1-3bi-luc, respectively. Furthermore, int1-3bi-luc construct containing mutations in both Sox-BE1 and BE2 sites led to an 85.2% reduction in luciferase activity. This suggests a cooperative function of the two Sox-BE binding sites in int1-3bi.
Sox-BE3mut also reduced Sox10-induced luciferase activity to 41.4%
of that of wt int1-3biii, although the extent of Sox10 to increase wild type int1-3biii enhancer activity was significantly lower than its ability to increase int1-3bi activity (9.5-fold vs 2-fold increase).
The direct binding of Sox10 to Sox-BE1-3 sequences was analyzed by electrophoretic mobility shift assay (EMSA; Figure 6d ). Incubation of labeled oligonucleotides spanning the Sox-BE1, 2, or 3 sequences with purified Sox10 amino terminal portion containing the DNA binding domain resulted in retardation of the labeled oligonucleotide bands.
The observed mobility shift was abolished when we added an excess of unlabeled wild type oligonucleotides as competitors but not mutant oligonucleotides that contained mutations in the Sox binding motifs.
| Identification of bHLH binding sites
We took a similar approach to identify bHLH-binding motifs in int1-3b.
In Neuro-2a cells, int1-3bi-luc and int1-3biii-luc but not int1-3bii-luc activity was increased in the presence of Ascl1 (Figure 7a) . Consistent with the lack of int1-3b-luciferase response to Olig2 + E47 shown in Figure 6a , Olig2 + E47 was less effective in increasing transcriptional activity of int1-3bi and int1-3biii. We scanned int1-3bi and int1-3biii subregions for sequences resembling the canonical bHLH binding motif CAXXTG (Chaudhary & Skinner, 1999) and found two putative sites in int1-3bi region, bHLH-BE1 (CAATCG) and bHLH-BE2 (CACGCG), and two additional sites in int1-3biii region, bHLH-BE3 (CAGCCAG) in the sense strand and bHLH-BE4 (CAGAAG) in the antisense strand. When we introduced scrambled mutations into the BE1 site in the int1-3bi luciferase construct, there was a general trend toward higher luciferase activity. This reached a statistically significant level only in the presence of Olig2 + E47 but not in control or in the presence of Ascl1 (Figure 7b, left) . It is possible that Olig2 binding to this region could repress transcription. By contrast, when we mutated the BE2 site in the int1-3bi luciferase construct, there was a reduction in luciferase activity compared with that obtained with wt int1-3i-luc construct, and this reached statistical significance in the presence of Olig2 + E47 and with Ascl1 (Figure 7b, left) . Mutation of the bHLH-BE3 sequence had no effect on int1-3biii luciferase activity in the presence of Olig2 + E47 but reduced the activity induced by Ascl1 (Figure 7b , right). Mutations in bHLH-BE4 had no effect on int1-3biii luciferase activity.
EMSA analysis showed retardation of labeled bHLH-BE1, 3, and 4 by Olig2 and Ascl1, which was diminished in the presence of excess unlabeled wild type but not mutant competitors (Figure 7c ), suggesting that bHLH-BE1, 3, and 4 were directly recognized by Olig2 and Ascl1. In the case of bHLH-BE4, addition of Olig2 or Ascl1 led to the formation of two species of retarded bands, both of which could be competed out by wild type but not mutant bHLH-BE4 oligonucleotides, suggesting multimeric binding. Interestingly, Sox and bHLH binding motifs in both int1-3bi and int1-3biii were located within 100 bp of one another. Therefore, the two classes of transcription factors may functionally interact to modulate Cspg4 transcription.
| Transcription factor binding sites are necessary for int1-3b enhancer activity in the brain
To examine whether Sox10 and bHLH binding sites were required for Cspg4 enhancer activity in vivo, we tested the ability of mutated int1-3b
to drive reporter expression after electroporation into the neonatal mouse brain. When we electroporated wild type Tol2-Cspg4-EGFP ( Figure 8a ) together with Tol2-CAG-mCherry and CAG-Transposase plasmids into P0 brain and analyzed the brains at P14, EGFP+ cells were found in the brain parenchyma, away from the site of electroporation (Figure 8b,d) . We next constructed a Tol2-Cspg4mut-EGFP reporter plasmid with scrambled mutations in the six transcription factor binding sites, Sox-BE1, 2, 3 and bHLH-BE1, 3, and 4. When the Tol2-Cspg4mut-EGFP plasmid was electroporated, no EGFP+ cells were observed even though mCherry+ cells were detected along the lateral ventricles in similar numbers to the brains electroporated with wild type Tol2-Cspg4-EGFP plasmid (Figure 8c,d) . These results suggest that the Sox10-and bHLH-binding elements within the Cspg4 int1-3b enhancer were required for Cspg4 transcription in NG2 glial cells in vivo.
To confirm that P0 electroporation could target NG2 glia, we verified the efficacy of electroporation by co-electroporating into P0 brain Tol2-CAG-mCherry plasmid encoding mCherry and the transposase plasmid (CAG-TPase). When the brains were analyzed at P14, there was widespread mCherry expression among GS+ astrocytes, Pdgfrα+ A previous study reported that a 1.5 kb mouse Cspg4 promoter sequence targets reporter expression to NG2 cells when used in a retroviral vector injected into injured CNS (Guo et al., 2014; Sellers et al., 2009 ). However, in our assays using primary mouse mixed glial cultures and chick in ovo electroporation, we did not detect reporter expression in NG2 cells with the 1.5 kb promoter. Moreover, the 1.5 kb promoter resulted in nonspecific reporter expression in neurons and GFAP+ astrocytes. In the Sellers study, 15% of the infected cells were reported to be GFAP+ astrocytes, and 10% were Iba1+ microglia. The long-terminal repeats of the retroviral vector rather than the promoter are likely to have primarily driven the expression of the reporter in the highly proliferative NG2 cells.
The 1.45 kb int1-3b enhancer in the first intron, which was the only noncoding region found to be conserved in chick and mammals, directed reporter expression specifically to NG2 glial cells and some oligodendrocytes in vitro and in vivo. While the majority of NG2 cells in Cspg4-EGFP1 transgenic mice expressed EGFP, there were some NG2 cells that did not express EGFP, possibly due to the absence of a critical promoter sequence that was not included in the construct and/or position effect of the integration site. We never detected EGFP expression in astrocytes, which suggests that int1-3b enhancer contains sequences critical for repressing transcription in astrocytes or that astrocytes lack the critical factor that activates enhancer.
In Cspg4-EGFP1 mice, EGFP expression was also detected in some CC1+ oligodendrocytes, although at a lower level than in NG2 cells. A small percentage of the EGFP+ cells that lacked Olig2 or Sox10 were likely to be mature myelinating oligodendrocytes (Muroyama, Fujiwara, Orkin, & Rowitch, 2005) . As it takes several days for NG2 cells to differentiate into oligodendrocytes, especially in older mice at P60, (Hill, Patel, Goncalves, Grutzendler, & Nishiyama, 2014; Zhu et al., 2011) , which is longer than the half-life of EGFP, the presence of EGFP in oligodendrocytes is likely due to weak activation of EGFP transcription in mature oligodendrocyte rather than residual EGFP protein that had been synthesized in NG2 cells prior to differentiation. The larger proportion of EGFP+ cells that were CC1+ oligodendrocytes in deeper cortical layers and corpus callosum at both P14
and P60 also suggests that the enhancer remains active in new oligodendrocytes. There are likely to be other silencing elements required for rapid downregulation of NG2 transcription during oligodendrocyte differentiation. For example, the 3 0 -UTR, which was not included in the Cspg4-EGFP1 mice, could contain sequences required for regulation by miRNAs, as shown for downregulation of PDGFRα expression during oligodendrocyte differentiation (Budde et al., 2010; Dugas et al., 2010; Zhao et al., 2010) . Notably, >99% of EGFP+ cells were
Olig2+ oligodendrocyte lineage cells.
In Cspg4-EGFP1 mice, very faint EGFP expression that was only slightly above background was detected in the subventricular zone and in some cortical neurons. In Cspg4-EGFP2 transgenic line that exhibited a higher level of EGFP, a more widespread distribution of EGFP was detected not only in oligodendrocyte lineage cells but also in neuronal cells (data not shown). By contrast, when the int1-3b enhancer was used to drive EGFP expression in a Tol2 construct by in vivo electroporation in the P0 brain, EGFP was expressed exclusively in NG2 cells (Figure 8 ). This suggests that cell type specificity of the enhancer could depend on copy number, and at low gene dosage, there is a higher degree of specificity. We did not observe EGFP expression in PDGFRβ+ pericytes at any of the ages examined, suggesting that NG2 expression in pericytes is regulated through different cis-regulatory elements. Thus, the Cspg4 int1-3b sequence will be useful for targeting genes specifically to NG2 glia and not pericytes.
| Sox10 and Olig2 binding to the Cspg4 int1-3b enhancer
We have shown that SoxE and bHLH transcription factors activated the Cspg4 int1-3b enhancer, and Olig2 and Sox10 were enriched at int1-3b sequence. Of the SoxE proteins which are Sox8, 9, and 10, Sox9 plays a critical role in the generation of parenchymal NG2 cells in the developing spinal cord. In the absence of Sox9, Olig2+ cells appear normally in the ventricular zone, but the appearance of NG2 cells in the parenchyma and the expression of NG2 and Sox10 are severely affected in the E12.5-E14.5 spinal cord (Stolt et al., 2003) .
Sox9 is downregulated in oligodendrocyte lineage cells beyond the first postnatal week (Finzsch et al., 2008; Stolt et al., 2003 Stolt et al., , 2006 Weider & Wegner, 2017) . By contrast, Sox10 persists through the lineage and has multiple roles at different stages of differentiation. Thus, Sox10 is likely to play a more prominent role in regulating NG2 expression in postnatal NG2 cells. Our mutation analysis revealed at least three Sox-binding sites in the int1-3b enhancer sequence, each of which partially contributed to activate NG2 transcription.
Mutations in both Sox10 BE1 and 2 putative binding sites reduced Sox10-dependent luciferase activity by 85% suggesting a cooperative role of Sox10. However, the distance between BE1 and 2 are farther than the reported binding sites for Sox10 dimer in other cell types (Peirano & Wegner, 2000) , and we did not see a supershifted band in Olig2 on the specification of PDGFRα+ OPCs in the telencephalon (Parras et al., 2007) . Within the two clusters of Sox and bHLH binding motifs in int1-3b, the Sox and bHLH binding motifs were within 100 bp of each other, providing further support for a functional interaction of the two families of transcription factors. Furthermore, the Sox family of proteins have been shown to directly interact with Olig2 (Wissmuller, Kosian, Wolf, Finzsch, & Wegner, 2006) . The inability of the mutated enhancer to direct EGFP transcription after delivery into neonatal mouse brain also supports the importance of these binding sites in the developing brain in vivo.
In conclusion, we have identified a novel 1.45 kb Cspg4 intronic enhancer that activates transcription in NG2 glial cells in vivo and is coordinately regulated by Sox10 and the bHLH transcription factors
Olig2 and Ascl1. The identification and characterization of the enhancer described here not only provides new insight into glial cellspecific transcription of Cspg4, but the enhancer can also be used as a tool for targeting genes specifically to oligodendrocyte lineage cells.
